NZ591311A - Treatment of acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct - Google Patents

Treatment of acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct

Info

Publication number
NZ591311A
NZ591311A NZ591311A NZ59131109A NZ591311A NZ 591311 A NZ591311 A NZ 591311A NZ 591311 A NZ591311 A NZ 591311A NZ 59131109 A NZ59131109 A NZ 59131109A NZ 591311 A NZ591311 A NZ 591311A
Authority
NZ
New Zealand
Prior art keywords
treatment
single chain
chain antibody
lymphoblastic leukemia
acute lymphoblastic
Prior art date
Application number
NZ591311A
Other languages
English (en)
Inventor
Gerhard Zugmaier
Evelyn Degenhard
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41692882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ591311(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of NZ591311A publication Critical patent/NZ591311A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ591311A 2008-11-07 2009-11-06 Treatment of acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct NZ591311A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US18329109P 2009-06-02 2009-06-02
PCT/EP2009/007970 WO2010052014A1 (fr) 2008-11-07 2009-11-06 Traitement de la leucémie lymphoblastique aiguë

Publications (1)

Publication Number Publication Date
NZ591311A true NZ591311A (en) 2012-10-26

Family

ID=41692882

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ591311A NZ591311A (en) 2008-11-07 2009-11-06 Treatment of acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct

Country Status (27)

Country Link
US (3) US20130323247A1 (fr)
EP (2) EP2342227B1 (fr)
JP (2) JP5647132B2 (fr)
KR (1) KR101695327B1 (fr)
CN (2) CN102209728A (fr)
AU (4) AU2009313040B2 (fr)
BR (1) BRPI0921482B1 (fr)
CA (1) CA2742249C (fr)
CY (2) CY1117033T1 (fr)
DK (2) DK2342227T3 (fr)
ES (2) ES2727585T3 (fr)
HK (2) HK1158668A1 (fr)
HR (2) HRP20151168T1 (fr)
HU (2) HUE028175T2 (fr)
IL (1) IL212652A (fr)
LT (1) LT2982696T (fr)
ME (2) ME02363B (fr)
MX (1) MX2011002927A (fr)
NZ (1) NZ591311A (fr)
PL (2) PL2982696T3 (fr)
PT (2) PT2342227E (fr)
RS (2) RS58827B1 (fr)
RU (1) RU2536940C2 (fr)
SI (2) SI2982696T1 (fr)
SM (1) SMT201500328B (fr)
WO (1) WO2010052014A1 (fr)
ZA (1) ZA201103255B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2532124T3 (es) * 2005-12-16 2015-03-24 Amgen Research (Munich) Gmbh Medios y procedimientos para el tratamiento de enfermedades tumorales
WO2010052014A1 (fr) * 2008-11-07 2010-05-14 Micromet Ag Traitement de la leucémie lymphoblastique aiguë
HUE025759T2 (en) 2009-10-27 2016-04-28 Amgen Res (Munich) Gmbh Dosage system for administering CD19xCD3 bispecific antibody
EP2632954B2 (fr) * 2010-10-27 2021-07-07 Amgen Research (Munich) GmbH Moyens et méthodes de traitement du lymphome b diffus à grandes cellules
RS55995B2 (sr) * 2010-11-10 2024-04-30 Amgen Res Munich Gmbh Prevencija neželjenih efekata uzrokovanih cd3-specifičnim vezujućim domenima
CA2832360C (fr) * 2011-04-28 2022-05-03 Amgen Research (Munich) Gmbh Regime posologique pour l'administration d'un anticorps bispecifique cd19xcd3 a des patients a risque d'eventuels effets indesirables
WO2012158818A2 (fr) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation
EP3105252B1 (fr) * 2014-02-12 2019-07-24 Michael Uhlin Anticorps bispécifiques utilisables dans une transplantation de cellules souches
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
FI3531133T3 (fi) 2014-05-30 2023-11-02 Amgen Res Munich Gmbh Prekursori-b-solujen akuutin lymfoblastisen leukemian potilaiden riskiluokittelu
SG11201701867SA (en) 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
US20180021331A1 (en) 2014-12-30 2018-01-25 University Of Utah Research Foundation Hdac1,2 inhibitors and methods of using the same
WO2016138071A1 (fr) 2015-02-24 2016-09-01 Short Jay M Protéines biologiques conditionnellement actives
CN114634943A (zh) 2015-05-18 2022-06-17 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
MX2017014731A (es) * 2015-05-20 2018-06-28 Amgen Res Munich Gmbh Eliminacion de linfocitos b como marcador diagnostico.
WO2016209921A1 (fr) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Polythérapies pour malignités hématologiques avec des anticorps anti-cd38 et des inhibiteurs de la survivine
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN105154440B (zh) * 2015-08-14 2016-11-30 深圳市瀚海基因生物科技有限公司 一种基于高通量测序构建白血病微小残留病灶tcr文库的多重pcr引物和方法
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MA43187B1 (fr) 2015-11-03 2021-02-26 Janssen Biotech Inc Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
RU2651776C2 (ru) * 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
EP3430058A4 (fr) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. Protéines de fusion à fab multispécifiques et leur utilisation
EP3494138A1 (fr) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions et méthodes de reprogrammation de tcr en utilisant des protéines de fusion
WO2018067993A1 (fr) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions et méthodes de reprogrammation des récepteurs des lymphocytes t faisant appel à des protéines de fusion
JP7291396B2 (ja) * 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
SG11202004273YA (en) * 2017-12-11 2020-06-29 Amgen Inc Continuous manufacturing process for bispecific antibody products
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
WO2020132810A1 (fr) * 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Protéines multispécifiques de liaison à l'antigène pouvant se lier à cd19 et cd3, et leur utilisation
WO2020232247A1 (fr) 2019-05-14 2020-11-19 Provention Bio, Inc. Procédés et compositions pour la prévention du diabète de type 1
US20230146593A1 (en) 2020-03-12 2023-05-11 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor
BR112022025381A2 (pt) 2020-06-11 2023-01-24 Provention Bio Inc Métodos e composições para prevenir diabetes tipo 1
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
KR20240099263A (ko) 2021-10-15 2024-06-28 암젠 리서치 (뮌헨) 게엠베하 Cd19 결합 t 세포 관여 항체의 피하 투여

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008875A1 (fr) * 1996-08-28 1998-03-05 Viva Diagnostika Diagnostische Produkte Gmbh Nouvelles preparations combinees et leur utilisation en immunodiagnostic et en immunotherapie
BG65066B1 (bg) * 1998-04-21 2007-01-31 Micromet Gessellschaft Fur Biomedicinische Forschung Mbh CD19 x CD3 СПЕЦИФИЧНИ ПОЛИПЕПТИДИ И ТЯХНОТО ИЗПОЛЗВАНЕ
DE69909459T2 (de) * 1998-04-21 2004-05-27 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
AU2004242846A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
KR101229731B1 (ko) * 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
ES2532124T3 (es) * 2005-12-16 2015-03-24 Amgen Research (Munich) Gmbh Medios y procedimientos para el tratamiento de enfermedades tumorales
CN101331151A (zh) * 2005-12-16 2008-12-24 麦克罗梅特股份公司 治疗肿瘤性疾病的方式和方法
AU2007285976B2 (en) * 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
WO2010052014A1 (fr) * 2008-11-07 2010-05-14 Micromet Ag Traitement de la leucémie lymphoblastique aiguë
CN104945311A (zh) * 2009-01-19 2015-09-30 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
NZ703941A (en) * 2009-01-19 2016-04-29 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102459236B (zh) * 2009-05-27 2014-10-29 Abbvie公司 激酶活性的嘧啶抑制剂
NZ598461A (en) * 2009-09-20 2013-12-20 Abbvie Inc Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
HUE025759T2 (en) * 2009-10-27 2016-04-28 Amgen Res (Munich) Gmbh Dosage system for administering CD19xCD3 bispecific antibody

Also Published As

Publication number Publication date
BRPI0921482B1 (pt) 2022-09-20
US20240109964A1 (en) 2024-04-04
US20190300609A1 (en) 2019-10-03
AU2017219083A1 (en) 2017-09-14
ES2558434T3 (es) 2016-02-04
EP2982696A3 (fr) 2016-02-17
HK1220705A1 (zh) 2017-05-12
BRPI0921482A2 (pt) 2016-01-12
SI2342227T1 (sl) 2015-12-31
SI2982696T1 (sl) 2019-06-28
HRP20151168T1 (hr) 2015-12-04
AU2009313040B2 (en) 2015-07-09
PT2982696T (pt) 2019-06-04
AU2018260815A1 (en) 2018-11-22
JP5647132B2 (ja) 2014-12-24
PL2342227T3 (pl) 2016-04-29
KR20110091668A (ko) 2011-08-12
RU2536940C2 (ru) 2014-12-27
IL212652A0 (en) 2011-07-31
AU2015238784A1 (en) 2015-10-29
US11597766B2 (en) 2023-03-07
CY1117033T1 (el) 2017-04-05
KR101695327B1 (ko) 2017-01-11
WO2010052014A1 (fr) 2010-05-14
CA2742249C (fr) 2020-07-21
RS58827B1 (sr) 2019-07-31
JP5955921B2 (ja) 2016-07-20
PL2982696T3 (pl) 2019-08-30
CY1122366T1 (el) 2021-01-27
DK2342227T3 (en) 2016-02-15
MX2011002927A (es) 2011-04-11
EP2982696A2 (fr) 2016-02-10
RU2011122819A (ru) 2012-12-20
AU2018260815B2 (en) 2020-03-05
CA2742249A1 (fr) 2010-05-14
US20130323247A1 (en) 2013-12-05
EP2342227A1 (fr) 2011-07-13
AU2009313040A1 (en) 2010-05-14
IL212652A (en) 2015-05-31
RS54456B1 (en) 2016-06-30
HUE028175T2 (en) 2016-12-28
ME03480B (fr) 2020-01-20
ZA201103255B (en) 2013-12-23
HRP20190912T1 (hr) 2019-07-26
EP2342227B1 (fr) 2015-10-07
BRPI0921482A8 (pt) 2017-07-11
HK1158668A1 (en) 2012-07-20
CN107184977A (zh) 2017-09-22
HUE043326T2 (hu) 2019-08-28
DK2982696T3 (da) 2019-05-27
ME02363B (me) 2016-06-20
ES2727585T3 (es) 2019-10-17
AU2017219083B2 (en) 2018-08-09
JP2012508164A (ja) 2012-04-05
EP2982696B1 (fr) 2019-03-27
JP2015057417A (ja) 2015-03-26
LT2982696T (lt) 2019-06-10
SMT201500328B (it) 2016-02-25
PT2342227E (pt) 2015-11-13
CN102209728A (zh) 2011-10-05

Similar Documents

Publication Publication Date Title
NZ591311A (en) Treatment of acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct
NZ591312A (en) Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
UA100874C2 (en) Bivalent bispecific antibodies
CL2007002667A1 (es) Uso de trastuzumab para la prevencion o reduccion de la metastasis en un paciente que padece de cancer her2 positivo, que no responde a una monoterapia con trastuzumab ni a una monoterapia con pertuzumab.
WO2007145862A3 (fr) Prolongation de la survie de patients cancéreux présentant des niveaux élevés d'egf ou de tgf-alpha
TW200640488A (en) Extending time to disease progression or survival in cancer patients
MX2010006823A (es) Metodos para el tratamiento de la gota.
NZ604056A (en) Novel anti-cmet antibody
UA101487C2 (en) Humanized b-ly1 antibody formulation
WO2009074792A3 (fr) Nouvelle utilisation
WO2007127263A3 (fr) Utilisations thérapeutiques d'urolithines
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
MX340424B (es) Compuestos novedosos de mimeticos de cambio inverso; metodo para fabricarlos y su uso.
NZ597531A (en) Inhibition of tumor metastasis using bv8- or g-csf-antagonists
EP4083071A3 (fr) Thérapie combinée d'un anticorps anti-cd19 avec un analogue de purine
MX2009005631A (es) Sulfuro de zinc transparente que tiene alta area superficial especifica.
MX354479B (es) Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.
MX2009009693A (es) Metodos para activar irs-1 y akt.
UA94781C2 (ru) Применение йота-каррагенана для профилактики или терапевтического лечения риновирусной инфекции
NO20092496L (no) Ny terapeutisk anvendelse for behandling av leukemi
MY166063A (en) Intravenous antiviral treatments
MX2011005054A (es) Uso combinado de bendamustina, doxorubicina y bortezomib para el tratamiento del mieloma multiple.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 06 NOV 2016 BY DENNEMEYER SA

Effective date: 20131017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2017 BY CPA GLOBAL

Effective date: 20160930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2018 BY CPA GLOBAL

Effective date: 20171005

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2019 BY CPA GLOBAL

Effective date: 20181004

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2020 BY CPA GLOBAL

Effective date: 20191003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2021 BY CPA GLOBAL

Effective date: 20201001

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2022 BY CPA GLOBAL

Effective date: 20210930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2023 BY ANAQUA SERVICES

Effective date: 20221022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2024 BY ANAQUA SERVICES

Effective date: 20231019